Edward MD - Third Harmonic Chief Officer
| THRD Stock | USD 12.76 0.35 2.67% |
Insider
Edward MD is Chief Officer of Third Harmonic Bio
| Age | 51 |
| Address | 1700 Montgomery Street, San Francisco, CA, United States, 94111 |
| Phone | (209) 727-2457 |
| Web | https://www.thirdharmonicbio.com |
Third Harmonic Management Efficiency
The company has return on total asset (ROA) of (0.1126) % which means that it has lost $0.1126 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1381) %, meaning that it created substantial loss on money invested by shareholders. Third Harmonic's management efficiency ratios could be used to measure how well Third Harmonic manages its routine affairs as well as how well it operates its assets and liabilities. As of November 30, 2024, Return On Tangible Assets is expected to decline to -0.12. In addition to that, Return On Capital Employed is expected to decline to -0.17. The current year's Debt To Assets is expected to grow to 0.02, whereas Total Assets are forecasted to decline to about 196.3 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| David MD | Passage Bio | N/A | |
| Michael Carruthers | Edgewise Therapeutics | 66 | |
| Jennifer Michaelson | Cullinan Oncology LLC | 57 | |
| Thomas Templeman | Nuvation Bio | 60 | |
| Path FRCP | Revolution Medicines | 61 | |
| Jeffrey Trigilio | Cullinan Oncology LLC | 40 | |
| Kerry Whalen | Cullinan Oncology LLC | N/A | |
| Jo PalmerPhillips | Eliem Therapeutics | N/A | |
| Elisabeth Colunio | Sensei Biotherapeutics | N/A | |
| Reid Leonard | Werewolf Therapeutics | 65 | |
| Michael Fischbach | Revolution Medicines | 43 | |
| Timothy CPA | Werewolf Therapeutics | 66 | |
| Ami Bavishi | Rallybio Corp | N/A | |
| Daniel Hicklin | Werewolf Therapeutics | 60 | |
| Arnold Levine | Pmv Pharmaceuticals | 84 | |
| Jennifer Champoux | Monte Rosa Therapeutics | N/A | |
| Jesper Olsen | Acrivon Therapeutics, Common | N/A | |
| Jeffrey CPA | Rallybio Corp | 54 | |
| Badreddin Edris | Edgewise Therapeutics | 37 | |
| Susan MS | Eliem Therapeutics | N/A | |
| MPH MBA | Sensei Biotherapeutics | N/A | |
Management Performance
| Return On Equity | -0.14 | ||||
| Return On Asset | -0.11 |
Third Harmonic Bio Leadership Team
Elected by the shareholders, the Third Harmonic's board of directors comprises two types of representatives: Third Harmonic inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Third. The board's role is to monitor Third Harmonic's management team and ensure that shareholders' interests are well served. Third Harmonic's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Third Harmonic's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Robert Ho, Chief Officer | ||
| Christopher Dinsmore, Chief Officer | ||
| Dennis Dean, Chief Officer | ||
| Gregg Keaney, VP Devel | ||
| Christopher Murphy, Chief Officer | ||
| Adrian Ray, Chief Officer | ||
| Ommer Chohan, Treasurer Secretary | ||
| Steven Sweeney, Senior Operations | ||
| Natalie Holles, CEO Director | ||
| Julie Person, Chief Officer | ||
| Edward MD, Chief Officer | ||
| Jennifer Dittman, Chief Officer |
Third Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Third Harmonic a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.14 | ||||
| Return On Asset | -0.11 | ||||
| Current Valuation | 298.03 M | ||||
| Shares Outstanding | 45.06 M | ||||
| Shares Owned By Insiders | 9.04 % | ||||
| Shares Owned By Institutions | 92.40 % | ||||
| Number Of Shares Shorted | 3.13 M | ||||
| Price To Earning | 23.13 X | ||||
| Price To Book | 2.00 X | ||||
| EBITDA | (30.79 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Third Harmonic Bio is a strong investment it is important to analyze Third Harmonic's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Third Harmonic's future performance. For an informed investment choice regarding Third Stock, refer to the following important reports:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Third Harmonic Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Third Harmonic. If investors know Third will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Third Harmonic listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.97) | Return On Assets (0.11) | Return On Equity (0.14) |
The market value of Third Harmonic Bio is measured differently than its book value, which is the value of Third that is recorded on the company's balance sheet. Investors also form their own opinion of Third Harmonic's value that differs from its market value or its book value, called intrinsic value, which is Third Harmonic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Third Harmonic's market value can be influenced by many factors that don't directly affect Third Harmonic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Third Harmonic's value and its price as these two are different measures arrived at by different means. Investors typically determine if Third Harmonic is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Third Harmonic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.